Immunology Investor Event

sanofi Immunology achievements since 2021 Capital Markets Day 1st DupixentⓇ COPD Study - BOREAS - completed enrollment Feb 2022 7 Phase 1 8 Phase 2 4 Phase 3 4 Pivotal Study Positive Readouts 5 Regulatory Submissions 3 Approvals DupixentⓇ CSU AD 6m - 5y EOE adult & adolescent DupixentⓇ AD 6m 5y (U.S., EU) AD pediatric 6-11y (CN) Asthma pediatric 6-11y (EU) EoE (U.S.) DupixentⓇ AD 12-17y (CN) Asthma 6-11y (U.S.) AD 6-11y (CN) itepekimab: COPD DupixentⓇ - PN - AFRS IRAK-4 degrader TNFα inhibitor oral anti-TNFα/OX40L NanobodyⓇ VHH anti-IL13/TSLP Nanobody® VHH anti-IL13/OX40L Nanobody® VHH anti-TNFα/IL23A Nanobody® VHH non-beta IL-2 amlitelimab: AD rilzabrutinib: (AD, CSU, Asthma) Topical BTKI (SAR'727): AD eclitasertib (RIPK1): CLE anti-CD40L: SLE, SJS CRSSNP CPUO These products are currently under clinical investigation and their safety and efficacy have not been evaluated by any regulatory authority. 2021 CMD: Sanofi Capital Markets Day, February 5, 2021 28 Immunology Investor Event

View entire presentation